WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $48.6 million in its first quarter. The Washington-based company said it had a loss of 82 cents ...

Thank you, Jordan. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals Inc.’s first quarter 2026 performance. Joining me on today’s call is Mihael H. Polymeropoulos, our ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ...

Shares of Vanda Pharmaceuticals (VNDA) have gained 8.5% over the past four weeks to close the last trading session at $7.56, ...

View Vanda Pharmaceuticals Inc. VNDA stock quote prices, financial information, real-time forecasts, and company news from CNN.

Preview this article 1 min It's the first new prescription medication for the condition in more than four decades and comes ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective ...

This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they ...

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...